Form 4: Opus Genetics Director Sean Ainsworth Receives RSU Grant

Director Sean Ainsworth was granted 24,367 restricted stock units in Opus Genetics, Inc. as part of a compensation event.

Summary

• Director Sean Ainsworth acquired 24,367 shares of common stock in the form of restricted stock units (RSUs).
• The transaction occurred on April 20, 2026.
• The shares were granted at a price of $0 per share.
• Following this transaction, the reporting person's total beneficial ownership is 321,692 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• The grant aligns the director's interests with those of shareholders through equity-based compensation.
• The director maintains a significant ownership stake of 321,692 shares.

Negatives

• None identified in this filing.

Risks

• Vesting of the RSUs is subject to the reporting person's continuing service through the vesting date.
• The value of the equity is subject to market volatility of the issuer's common stock.

Future Outlook

The RSUs vest on the earlier of the one-year anniversary of the grant date or the day prior to the issuer's next annual meeting of stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure long-term alignment between board members and company performance.

Comparison to Industry Standards

• The use of RSUs for director compensation is consistent with standard practices for publicly traded biotech companies.
• The vesting schedule of one year or the next annual meeting is a common retention mechanism in the industry.

Stakeholder Impact

• Shareholders may view the equity grant as a standard alignment of director incentives.

Next Steps

• Vesting of the 24,367 RSUs on the earlier of April 20, 2027, or the day prior to the next annual meeting.

Key Dates

Keywords

Opus Genetics, IRD, Form 4, Insider Trading, Director Compensation, Restricted Stock Units